Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 2678Pancreatic Neoplasms 1470Colonic Neoplasms 1159Carcinoma, Hepatocellular 1142Stomach Neoplasms 1127Rectal Neoplasms 980Esophageal Neoplasms 728Neoplasms 559Liver Neoplasms 533Breast Neoplasms 473Neoplasm Metastasis 373Lung Neoplasms 325Carcinoma, Non-Small-Cell Lung 292Gastrointestinal Neoplasms 277Ovarian Neoplasms 258Prostatic Neoplasms 229Cholangiocarcinoma 221Head and Neck Neoplasms 180Gastrointestinal Stromal Tumors 176Melanoma 165Esophageal Squamous Cell Carcinoma 164Barrett Esophagus 156Uterine Cervical Neoplasms 151Biliary Tract Neoplasms 149Adenocarcinoma Of Esophagus 148Gallbladder Neoplasms 136Carcinoma, Renal Cell 134Urinary Bladder Neoplasms 132Sarcoma 131Anus Neoplasms 124

Interventions

Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Attenuated familial adenomatous polyposis × Gastrointestinal × Clear all
NCT02961374 2022-07-26

Erlotinib Hydrochloride in Reducing Duodenal Polyp Burden in Patients With Familial Adenomatous Polyposis at Risk of Developing Colon Cancer

National Cancer Institute (NCI)

Phase 2 Completed
46 enrolled 13 charts
Gastrointestinal

Attenuated familial adenomatous polyposis, Adenomatous Polyposis Coli

Data powered by HemOnc (CC BY 4.0) Colophon âš¡